Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Four-Drug cocktail tame pancreatic cancer? a Real-World trial seeks answers

NCT ID NCT07723261

Disease control Sponsor: Hellenic Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study follows about 70 people with metastatic pancreatic cancer who are receiving NalIriFOx as their first treatment. Researchers are collecting real-world data to see how well the drug combination controls the disease and what side effects occur. The goal is to understand whether this regimen offers meaningful long-term benefits in everyday clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a combination of liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin (NalIriFOx)
What this could lead to
If the data show strong real-world effectiveness, this could support NalIriFOx as a standard first-line option for metastatic pancreatic cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects from the chemotherapy combination can be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with mPDAC receiving NalIriFOx as first line therapy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with histologically or cytologically proven metastatic PDAC * 1st line treatment with NalIriFOx according to physician's choice * Patients willing to provide a Written Informed Consent Exclusion Criteria: * Patients not matching the above-mentioned inclusion criteria * Neoadjuvant or adjuvant treatment within 6 months from enrolment * Prior treatment with Liposomal irinotecan * Prior treatment of pancreatic cancer in the metastatic setting with chemotherapy or investigational therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic ductal adenocarcinoma (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic pancreatic ductal adenocarcinoma (PDAC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 2nd Oncology Department, Metropolitan Hospital

    RECRUITING

    Athens, 185 47, Greece

  • Attikon University General Hospital

    RECRUITING

    Athens, 124 62, Greece

  • General Hospital Agios Andreas

    RECRUITING

    Pátrai, 263 32, Greece

  • General Oncology Hospital Agioi Anargyroi

    RECRUITING

    Athens, 145 64, Greece

  • HYGEIA Hospital

    RECRUITING

    Athens, 151 23, Greece

  • HYGEIA Hospital

    RECRUITING

    Athens, 151 23, Greece

  • Ippokratio

    RECRUITING

    Athens, Greece

  • Larissa University General Hospital

    RECRUITING

    Larissa, Greece

  • Thessaloniki General Hospital "George Papanikolaou"

    RECRUITING

    Thessaloniki, 570 10, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.